Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients

Jacob W. Glickman; Celina Dubin; Joseph Han; Dante Dahabreh; Sandra Garcet; James G. Krueger; Ana B. Pavel; Emma Guttman-Yassky

doi:10.1016/j.jaci.2020.01.005

Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients

Jacob W. Glickman, Celina Dubin, Joseph Han, Dante Dahabreh, Sandra Garcet, James G. Krueger, Ana B. Pavel, Emma Guttman-Yassky

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Original language	English
Pages (from-to)	1285-1288
Number of pages	4
Journal	Journal of Allergy and Clinical Immunology
Volume	145
Issue number	4
DOIs	https://doi.org/10.1016/j.jaci.2020.01.005
State	Published - Apr 2020

Access to Document

10.1016/j.jaci.2020.01.005

Cite this

@article{ed0640f64c3e48a8a12a06f259cbebc9,

title = "Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients",

author = "Glickman, {Jacob W.} and Celina Dubin and Joseph Han and Dante Dahabreh and Sandra Garcet and Krueger, {James G.} and Pavel, {Ana B.} and Emma Guttman-Yassky",

note = "Funding Information: Disclosure of potential conflict of interest: E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie, Celgene, Eli Lilly, Janssen, Medimmune/Astra Zeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB; and is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, AbbVie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. J. G. Krueger has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, BiogenIdec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2020",

month = apr,

doi = "10.1016/j.jaci.2020.01.005",

language = "English",

volume = "145",

pages = "1285--1288",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "4",

}

TY - JOUR

T1 - Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients

AU - Glickman, Jacob W.

AU - Dubin, Celina

AU - Han, Joseph

AU - Dahabreh, Dante

AU - Garcet, Sandra

AU - Krueger, James G.

AU - Pavel, Ana B.

AU - Guttman-Yassky, Emma

N1 - Funding Information: Disclosure of potential conflict of interest: E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie, Celgene, Eli Lilly, Janssen, Medimmune/Astra Zeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB; and is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, AbbVie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. J. G. Krueger has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, BiogenIdec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2020/4

Y1 - 2020/4

UR - http://www.scopus.com/inward/record.url?scp=85079682175&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2020.01.005

DO - 10.1016/j.jaci.2020.01.005

M3 - Article

C2 - 31954776

AN - SCOPUS:85079682175

SN - 0091-6749

VL - 145

SP - 1285

EP - 1288

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 4

ER -